Action of Clathrodin and analogues on voltage-gated sodium channels by Peigneur, S. et al.
Mar. Drugs 2014, 12, 2132-2143; doi:10.3390/md12042132 
 
marine drugs 
ISSN 1660-3397 
www.mdpi.com/journal/marinedrugs 
Article 
Action of Clathrodin and Analogues on Voltage-Gated  
Sodium Channels 
Steve Peigneur 
1,†, Aleš Žula 2,†, Nace Zidar 2, Fiona Chan-Porter 3, Robert Kirby 3,  
David Madge 
3, Janez Ilaš 2, Danijel Kikelj 2 and Jan Tytgat 1,* 
1
 Catholic University Leuven (KULeuven), Toxicology and Pharmacology, Herestraat 49-Box 922, 
3000 Leuven, Belgium; E-Mail: steve.peigneur@pharm.kuleuven.be 
2 University of Ljubljana, Faculty of Pharmacy, Aškerčeva 7, 1000 Ljubljana, Slovenia;  
E-Mails: ales.zula@ffa.uni-lj.si (A.Ž.); nace.zidar@ffa.uni-lj.si (N.Z.); janez.ilas@ffa.uni-lj.si (J.I.);  
danijel.kikelj@ffa.uni-lj.si (D.K.) 
3 
Xention Ltd., Iconix Park, London Road, Pampisford, Cambridge CB22 3EG, UK;  
E-Mails: fionachan31@yahoo.co.uk (F.C.-P.); robert.kirby@xention.com (R.K.); 
david.madge@xention.com (D.M.) 
†
 These authors contributed equally to this work. 
* Author to whom correspondence should be addressed; E-Mail: jan.tytgat@pharm.kuleuven.be;  
Tel.: +32-16-323403; Fax: +32-16-323405. 
Received: 3 January 2014; in revised form: 21 February 2014 / Accepted: 25 March 2014 /  
Published: 4 April 2014 
 
Abstract: Clathrodin is a marine alkaloid and believed to be a modulator of voltage-gated 
sodium (NaV) channels. Since there is an urgent need for small molecule NaV channel 
ligands as novel therapeutics, clathrodin could represent an interesting lead compound. 
Therefore, clathrodin was reinvestigated for its potency and NaV channel subtype 
selectivity. Clathrodin and its synthetic analogues were subjected to screening on a broad 
range of NaV channel isoforms, both in voltage clamp and patch clamp conditions. Even 
though clathrodin was not found to exert any activity, some analogues were capable of 
modulating the NaV channels, hereby validating the pyrrole-2-aminoimidazole alkaloid 
structure as a core structure for future small molecule-based NaV channel modulators. 
Keywords: clathrodin; oroidin; hymenidin; voltage-gated sodium channels;  
sodium channel modulator; sponge 
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1. Introduction 
Marine organisms, such as sea anemones, cone snails, fish, algae and sponges, among others, are 
known to produce peptide and non-peptide toxins targeting ion channels. The majority of marine 
toxins have been characterized to act upon voltage-gated sodium (NaV) channels. These molecules 
exhibit their toxicity by either physically inhibiting the sodium ion flow through the channel or by 
modifying the kinetics of channel gating [1]. Clathrodin (1) is a 2-aminoimidazole alkaloid containing 
an unsubstituted pyrrole 2-carboxamide moiety, isolated from the Caribbean sea sponge, Agelas 
clathrodes, which is structurally related to its 2,3-dibromopyrrole analogue, oroidin, from the sponge, 
Agelas oroides, and 2-bromopyrrole analogue hymenidin from the sponge, Hymeniacidon sp. [2–4]. 
Clathrodin was shown, in experiments performed in cells isolated from chick embryo sympathetic 
ganglia using the whole cell configuration of the patch clamp technique, to possess neurotoxic activity. 
It decreased the average maximum amplitudes of isolated inward sodium currents by 30%. 
Electrophysiological experiments indicated that clathrodin had no effect on the voltage dependence of 
current activation. However, the voltage dependence of current inactivation was shifted towards more 
positive potentials, and the V1/2 of inactivation was changed by 14 mV, while no alteration of the time 
for current reactivation was observed. Clathrodin thus appeared to be a new sodium channel 
neurotoxin influencing sodium channel ionic conductance [5]. The exact site of interaction of 
clathrodin with the NaV channel, as well as its subtype selectivity remained unknown [1]. Despite the 
fact that in the last 15 years, major progress has been made in understanding the structure and 
physiology of NaV channels, together with an intensive quest for small molecules targeting NaV 
channels as novel lead compounds for drug discovery [6–8], no further investigations on these three 
marine alkaloids have been reported. Aiming at using clathrodin as a possible lead for the design of 
NaV channels modifiers with therapeutic potential, we decided to reinvestigate the effect of clathrodin 
and to determine its selectivity profile for different NaV channel isoforms. This was done by 
combining the two-electrode voltage-clamp expression system with a high-throughput QPatch 
screening system. Additionally, with the aim of exploring preliminary structure activity relationship, 
we included in this study also the brominated analogues, oroidin (2) and hymenidin (3), as well as 
dihydroclathrodin (4), possessing a saturated linker between the 2-aminoimidazole core and the 
pyrrole-carboxamide moiety, two compounds in which the pyrrole is replaced by a phenyl (5) or the 
indole ring (6) and dihydroclathrodin derivative 7, containing an additional dipyrrole ring attached to 
the 2-aminoimidazole core. Furthermore, conformationally restricted clathrodin analogues, 8 and 9, 
containing a 1,3-phenylene linker between the 2-aminoimidazole core and the indole-carboxamide 
moieties were included in the study (Figure 1). 
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Figure 1. Structures of clathrodin (1), oroidin (2), hymenidin (3), dihydroclathrodin (4) 
and synthetic Analogues 5, 6, 7, 8 and 9 are shown. 
 
2. Results and Discussion 
2.1. Results 
Clathrodin, oroidin, hymenidin and their synthetic analogues (Figure 1) were subjected to testing 
against a broad panel of voltage-gated sodium channels. Electrophysiological experiments were 
performed both under voltage clamp conditions, using Xenopus laevis oocytes, as well as under patch 
clamp conditions, using Chinese hamster ovary [9] cells. In both expression systems, no activity was 
observed for clathrodin, oroidin, hymenidin or the analogues, 4, 5, 6 and 7, even at concentrations up 
to 10 μM (Figure 2). However, the synthetic analogues, 8 and 9, did show activity against several NaV 
channel isoform subtypes. The application of 10 μM of Compound 8 resulted in an increase of the 
peak current of NaV1.2 and NaV1.4–NaV1.6, but not of NaV1.3, NaV1.7, NaV1.8 and the insect channel, 
BgNaV1.1 (Figure 3). Furthermore, a slowing down of the inactivation was observed for NaV1.2 and 
NaV1.4–Nav1.6 channels after the addition of 8. The midpoint of the steady-state inactivation curve of 
NaV1.4 channels shifted non-significantly from −68.4 ± 0.3 mV in control conditions to −67.3 ± 0.9 mV 
after application of 10 μM of Compound 8, while no significant alteration of the V1/2 of activation was 
noted (Figure 4a, left panel). When applying a high concentrations (>200 μM) of Compound 8,  
a decrease of the sodium current peak amplitude could be observed. A 250 μM concentration of 8 
decreased the current peak amplitude of NaV1.6 channels by 94.6% ± 2.2% (n = 4). The activation 
curves shifted significantly from −14.2 ± 0.3 mV in control conditions towards 0.9 ± 0.1 mV in the 
presence of Compound 8. The midpoint of the inactivation curves shifted from −49.5 ± 0.9 mV in 
control conditions to −31.3 ± 0.5 mV (Figure 4b, left panel). These results were in concordance with 
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the data obtained from the patch clamp experiments. Analysis of the QPatch experiments showed that 
10 μM (8) caused a slowing down of the inactivation of the channels, both in the resting state  
(Figure 4c, right panel) and in the inactivated state (Figure 4c, left panel). Furthermore, in concordance 
with the voltage-clamp experiments, an increase in the sodium current peak amplitude was observed in 
the inactivated state (Figure 4c, left panel). 
Figure 2. Activity profile of clathrodin on several NaV channel isoforms. Representative 
whole-cell current traces in control and compound conditions are shown. The dotted line 
indicates the zero-current level. The arrow marks steady-state current traces after the 
application of 10 μM of clathrodin. The traces shown are representative traces of at least 
three independent experiments (n ≥ 3). 
 
Figure 3. Activity profile of Compound 8 on several NaV channel isoforms. Representative 
whole-cell current traces in control and compound conditions are shown. The dotted line 
indicates the zero-current level. The arrow marks steady-state current traces after the 
application of 10 μM of Compound 8. The traces shown are representative traces of at least 
three independent experiments (n ≥ 3). 
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Figure 4. Electrophysiological characterization of Compound 8 on NaV1.4 (A,C) and 
NaV1.6 (B) channels under voltage clamp (A,B) and patch clamp (C) conditions. (A, left 
panel) Representative whole-cell current traces of NaV1.4 in control and 10 μM of 
Compound 8 conditions are shown; (right panel) steady-state activation and inactivation 
curves in control (closed symbols) and compound conditions (open symbols). (B, left 
panel) Representative whole-cell current traces of NaV1.6 in control and 250 μM of 
Compound 8 conditions are shown; (right panel) steady-state activation and inactivation curves 
in control (closed symbols) and compound conditions (open symbols). (C) Representative 
current traces of NaV1.4 in the control and 10 μM of compound conditions are shown in the 
resting state (left panel) and the inactivated state (right panel). The asterisk (*) marks the 
steady-state current traces after the application of 10 μM of Compound 8. 
 
The screening of Compound 9 indicated that this compound, at a concentration of 1 μM, is capable 
of inhibiting the current through NaV1.4 and NaV1.5 channels (Figure 5a). Compound 9 did not show a 
significant affinity for the other NaV channel isoforms tested. The application of 1 μM of 9 inhibited  
46.3% ± 2.4% and 19.6% ± 1.3% of the NaV1.4 (n = 5) and NaV1.5 (n = 5) channels, respectively. 
Cells heterologously expressing Nav1.4 channels were used to investigate if the observed inhibition 
results from a physical blocking of the pore or rather from a modulation of the kinetics of channel 
gating. At a 1-μM concentration of Compound 9, no significant alteration in the characteristics of 
activation or inactivation was observed (Figure 5b, left panel). A concentration-response curve was 
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constructed in order to assess the affinity of Compound 9 for NaV1.4 channels. The IC50 value yielded 
3.5 ± 0.9 μM (Figure 5b, right panel). QPatch data showed that 10 μM of Compound 9 inhibits 40% of 
the sodium current through NaV1.4 channels in the inactivated state, but not in the resting state  
(Figure 5c). 
Figure 5. Electrophysiological characterization of Compound 9 under voltage clamp (A) 
and patch clamp (C) conditions. (A) Representative whole-cell current traces of NaV1.4 
and NaV1.5 in the control and 1 μM of Compound 9 conditions are shown. The asterisk (*) 
marks the steady-state current traces after the application of 1 μM of Compound 9.  
(B, left panel) At a 1-μM concentration of Compound 9, no significant alteration in the 
characteristics of activation or inactivation was observed; (B, right panel) The 
concentration-response curve of Compound 9 for NaV1.4 channels. The IC50 value yielded 
3.5 ± 0.9 μM. (C) The representative current traces of NaV1.4 in the control and 10 μM of 
Compound 9 conditions are shown in the resting state (left panel) and the inactivated state 
(right panel). The asterisk (*) marks the steady-state current traces after the application of 
10 μM of Compound 9. 
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2.2. Discussion 
It has been well recognized that NaV channels play a crucial role in inherited diseases, such as 
cardiovascular arrhythmias, central nervous system disorders and pain syndromes. This knowledge 
highlights NaV channel isoforms as targets of novel compounds that will hopefully fulfil the unmet 
therapeutic need to successfully treat these disorders [8,10]. Therefore, small molecules capable of 
selective targeting and modulation of NaV channel isoforms represent attractive pharmacological tools, 
either to identify the specific isoform involved in different channelopathies or as potential therapeutics. 
Over the last few decades, a number of compounds with promising pharmacological activity have been 
characterized from marine organisms. Several of these compounds have entered clinical trials or have 
been approved as drugs [11,12]. The marine alkaloid, clathrodin, isolated from the sponge, Agelas 
clathrodes, was reported to interact with NaV channels. Patch clamp experiments on cells isolated from 
sympathetic ganglia of chick embryo indicated that clathrodin decreased the average maximum 
amplitude of inward sodium currents by approximately 30%, while shifting the voltage dependence of 
inactivation towards more negative potentials. Furthermore, voltage clamp experiments, using frog 
muscle, confirmed these results, since an early potentiation followed by complete inhibition of sodium 
currents was observed after the application of clathrodin. Surprisingly, in our hands, when testing 
clathrodin, oroidin, hymenidin and their analogues, Analogues 4–6, no activity was observed, neither 
under voltage clamp nor patch clamp conditions. The lack of activity could be explained by different 
experimental conditions, such as different cells to express channels, potential differences in the 
posttranslational modifications of channels and differences in the expression of auxiliary subunits. 
Furthermore, the need for multiple pharmacological manipulations to isolate a specific type of channel 
current in tissue preparations, which are unnecessary in Xenopus oocytes or mammalian cells, and 
differences in membrane composition together with inherent differences in the osmolarity of the 
recording solutions, can provide an explanation for the differences observed between our experiments 
and earlier reports [5]. Nevertheless, from the experiments done in this work, it can be concluded that 
clathrodin does not interact with human NaV channels and, therefore, is not further considered as a 
possible lead for the development of novel therapeutics targeting NaV channels. 
Based upon the clathrodin structure, a series of analogues have been synthesized and tested on the 
modulation of NaV channels. Interestingly, one structural family of analogues (including Compounds 8 
and 9), in which a phenyl group was used to constrain the conformational freedom in the linker 
between the 2-aminoimidazole and indole cores, did show activity on NaV channels. Both Compounds 
8 and 9 showed NaV channel activity, although it seems that they interact differently with the channels. 
At lower concentrations, Compound 8 alters the voltage dependence of steady-state inactivation, 
causing a slowing down of the inactivation of NaV channels, which results in sustained  
non-inactivating currents. This effect is typically observed for certain scorpion toxins acting on NaV 
channels (α-NaScTx) [13]. These peptide toxins bind at the so-called neurotoxin binding Site 3. This 
site is mainly located at the extracellular loops between the S3 and S4 segments of Domain IV of the 
sodium channel. α-NaScTx interacts with the channel in the closed state, stabilizing the S4 voltage 
sensor of Domain IV in its inward position and, thereby, impairing the conformational changes 
necessary for fast inactivation [14]. However, Compound 8 differs from α-NaScTx in its 
characteristics of channel modulation when higher concentrations of the compound are applied. At 
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higher concentrations, a decrease of the sodium current peak amplitude could be observed. Whether 
this inhibition resulted from the strong shift in the V1/2 of both the activation and inactivation curves or 
rather from a reduction of the sodium conductance remains to be elucidated. Other alkaloids acting on 
NaV channels, such as batrachotoxin (BTX), veratridine (VTD), aconitine and grayanotoxins, are also 
capable of reducing the sodium conductance. However, with BTX, this reduction is accompanied by 
several changes in channel properties, which are not seen upon the application of Compound 8. When 
binding at neurotoxin Site 2, BTX will: (i) shift the voltage-dependence of activation toward a more 
negative potential; (ii) cause the inactivation to be slowed down or inhibited, resulting in sustained, 
non-inactivating currents; (iii) cause the sodium conductance through toxin-bound channels to be 
reduced; and (iv) cause the ion selectivity of modified channels to be altered due to a decreased 
discrimination for permeating ions [15,16]. Further structure-function studies, together with binding 
experiments, are required to verify which neurotoxin site is targeted by Compound 8. 
For Compound 9, the inhibition of channels without an alteration of gating kinetics was observed, 
suggesting that the inhibition results from a physical obstruction of the sodium ion pathway. 
Tetrodotoxin (TTX) and saxitoxin (STX) are two marine alkaloids known to inhibit NaV channels. 
STX and TTX are the most studied and well characterized members of the large family of 
guanidinium-containing marine compounds. Even though STX and TTX and their respective 
analogues belong to structurally divergent families, they do bind with high affinity to the same target, 
the neurotoxin receptor Site 1 of NaV channels [14,17]. Upon binding at a narrow part within the 
channel pore, they obstruct the ion conductance through the channels by physically blocking the 
pathway of the Na
+
 ions. Similar to Compound 9, neither toxin significantly alters the kinetics of 
gating. Although Compound 9 exerts a similar pharmacological activity upon binding to NaV channels, 
it should be noted that it is structurally unrelated to the guanidinium toxins TTX and STX. Therefore, 
further structure-function studies combined with site-directed mutagenesis experiments are required to 
verify whether or not Compound 9 interacts with the neurotoxin receptor Site 1 of NaV channels. 
3. Experimental Section 
3.1. Compound Synthesis 
Clathrodin (1), oroidin (2) and hymenidin (3) were synthesized by a modified procedure of  
Al-Mourabit et al. [18]. Dihydroclathrodin (4) was obtained by acylation of  
2-amino-4-(3-aminopropyl)imidazole prepared from L-ornithine by the improved synthesis of  
Olofson et al. [19,20]. Compounds 5, 6 and 7 were prepared by acylation of  
3-amino-1-(2-aminoimidazol-4-yl)prop-1-ene [20]. Compounds 8 and 9 were prepared by coupling of 
tert-butyl 2-amino-4-(3-aminophenyl)-1H-imidazole-1-carboxylate and indole-2- or indole-3-carboxylic 
acid, as described [21]. The purity of the tested compounds was established to be >95% by HPLC 
analysis (Agilent Technologies HP 1100 instrument with a G1365B UV-Vis detector, using an Agilent 
Eclipse plus C18 column (4.6 × 150 mm, Technologies, Santa Clara, CA, USA) and a mixture of  
0.1% NH3 in water (A) and methanol (B) as the eluent. The gradient was 10% B to 70% in 20 min at a 
flow rate 1 mL/min). 
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3.2. Electrophysiology 
Patch clamp experiments: Cells were prepared by dissociation from T175 cell culture flasks using 
trypsin-EDTA (0.05%). Cells were kept in serum-free media in the cell hotel on-board the QPatch HT. 
These cells were sampled, washed and re-suspended in extracellular recording solution by the QPatch 
HT immediately before the application to the well site on the chip. Once in whole-cell configuration, 
the vehicle (0.1% DMSO v/v) was applied to the cells to achieve a stable control recording (4 min 
total). This was followed by the application of test concentrations as a single bolus addition (4-min 
incubation per test concentration). Compounds were prepared in extracellular recording solution from 
a 10-mM (100% DMSO) stock to yield a final 10-μM (0.1% DMSO) test concentration from which 
subsequent serial dilutions in extracellular solution were performed (0.3–10 μM). Currents were 
elicited from Nav1.3, Nav1.4 and Nav1.7 cell lines using a standard two-pulse voltage protocol. From 
a holding potential of −100 mV; a 20-ms activating step to −20 mV was applied to assess the effect of 
compounds on the resting (closed) state block. The second activating pulse was applied following a  
5-second pre-pulse to half inactivation potential (variable, depending on the sodium channel studied, 
−65 to −75 mV) to assess the block on the open-inactivated state of the channel. This protocol was 
applied at a sweep interval of 0.067 Hz throughout the duration of the experiment. To study NaV1.5 
currents, a pulse train consisting of 10 repetitive activating test pulses to −20 mV from a holding 
potential of −100 mV were applied at a 1-Hz frequency until 10 pulses were reached; this sequence was 
repeated at a sweep interval of 0.016 Hz throughout the duration of the experiment. For NaV1.3, NaV1.4 
and NaV1.7 channels, the peak inward current was determined for both the closed and open-inactivated 
test pulses from each sweep applied to the cells and for NaV1.5 from the tenth pulse of each pulse train 
recorded. Data was captured using QPatch assay software (v5.0). The percent of inhibition of the peak 
current was calculated as the mean peak current value for the last three sweeps measured in each 
concentration test period relative to the last three sweeps recorded during the control vehicle period. 
Sigmoidal concentration response curves (four parameter logistic curves) were fitted to the percent of 
inhibition data using Xlfit (IDBS), from which the IC50 was determined. Fits were constrained at 0% 
and 100%. Data are presented as the mean ± SD for a minimum of 3 independent observations. 
3.3. Two-Electrode Voltage Clamp 
3.3.1. Heterologous Expression 
For expression in X. laevis oocytes, NaV1.3/pLCT2 (NotI), NaV1.4/pUI-2 (NotI), NaV1.7/pBSTA.rPN1 
(SacII) and hβ1/pGEM-HE (NheI) were linearized with the respective restriction enzymes, mentioned 
between parentheses, and transcribed using the T7 mMESSAGE-mMACHINE transcription kit (Ambion, 
Austin, TX, USA). hNaV1.5/pcDNA3.1 (XbaI) was linearized with the respective restriction enzyme, 
mentioned between parentheses, and transcribed with the SP6 mMESSAGE-mMACHINE transcription 
kit (Ambion, Austin, TX, USA). Stages V and VI oocytes, harvested from anesthetized female 
X. laevis frogs, as described previously [22], were injected with 30–50 nL of 1–3 μg/μL NaV channel 
cRNA using a micro-injector (Drummond Scientific, Broomall, PA, USA). The oocytes were then 
incubated in ND96 solution (in mM: NaCl 96, KCl 2, MgCl2 1, CaCl2 1.8, HEPES 5), adjusted to  
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pH 7.5 and supplemented with 50 mg/L of gentamycin sulphate and 90 mg/L theophylline, at 16 °C for  
1–5 days, until the expression of ion channels. 
3.3.2. Electrophysiological Characterization 
Two-electrode voltage-clamp (TEVC) recordings were performed at room temperature using a 
GeneClamp 500 amplifier (Molecular Devices, Sunnyvale, CA, USA) controlled by a pClamp data 
acquisition system (Molecular Devices). Whole-cell currents from oocytes were recorded 1–5 days after 
injection. Voltage and current electrodes were filled with 3 M KCl. The resistances of both electrodes 
were kept between 0.7 and 1.7 MΩ. The elicited currents were sampled at 20 kHz and filtered at 2 kHz 
using a four-pole, low-pass Bessel filter. To eliminate the effect of the voltage drop across the  
bath-grounding electrode, a two-electrode bath clamp actively controlled the bath potential. Leak 
subtraction was performed using a −P/4 protocol. For the electrophysiological characterization of the 
compounds, a number of voltage protocols were applied from a holding potential of −90 mV with a 
start-to-start pulse frequency of 0.2 Hz. Current traces were evoked in oocytes expressing the cloned 
NaV channels according to the following protocol: from a holding potential of −90 mV, current traces 
were evoked by 100-ms depolarizations to the voltage corresponding to the maximal activation of the 
NaV channel subtype in control conditions. All data were tested for normality using a D’Agustino 
Pearson omnibus normality test. Data following a Gaussian distribution were analysed for significance 
using one-way ANOVA and the Bonferroni test. Non-parametric data were analysed for significance 
using the Kruskal-Wallis and Dunn’s test. 
4. Conclusions 
There is increasing evidence not only regarding the important role of NaV channels in 
channelopathies, but also their crucial contribution in chronic pain. Consequently, there is an urgent 
need for novel therapeutics targeting NaV channels. Based on previous work, we reinvestigated 
whether or not clathrodin and its analogues are suitable as leads in the development of novel therapeutics 
exerting a pharmacological activity through an interaction with NaV channels. In this work, we show that 
clathrodin does not interact with NaV channels. However, two analogues of clathrodin, Compound 8 and 
9, are capable of modulating NaV channels. Unfortunately, these compounds showed affinity for a 
broad range of NaV channels with a low potency. Nevertheless, these compounds might serve as 
templates for the development of more selective and potent compounds in future studies. 
Acknowledgments 
This work was supported by the European Union FP7 Integrated Project MAREX: Exploring 
Marine Resources for Bioactive Compounds: From Discovery to Sustainable Production and Industrial 
Applications (Project No. FP7-KBBE-2009-3-245137); and by the Slovenian Research Agency (Grant 
No. P1-0208 and Grant No. Z1-5458). Jan Tytgat was supported by the following grants: G.0433.12, 
G.A071.10N and G.0257.08 (Fonds Wetenschappelijk Onderzoek Vlaanderen) and OT/12/081 
(Katholieke Universiteit Leuven). 
  
Mar. Drugs 2014, 12 2142 
 
 
Author Contributions 
Planned experiments: Steve Peigneur, Jan Tytgat, Danijel Kikelj, David Madge and  
Fiona Chan-Porter. Performed experiments: Steve Peigneur, Aleš Žula, Nace Zidar, Robert Kirby and 
Janez Ilaš. Analysed data: Steve Peigneur, Aleš Žula, Fiona Chan-Porter, Robert Kirby, David Madge, 
Danijel Kikelj and Jan Tytgat. Contributed reagents or other essential material: David Madge,  
Danijel Kikelj and Jan Tytgat. Wrote the paper: Steve Peigneur, Fiona Chan-Porter, David Madge, 
Danijel Kikelj and Jan Tytgat. 
Conflicts of Interest 
The authors declare no conflict of interest. 
References  
1. Al-Sabi, A.; McArthur, J.; Ostroumov, V.; French, R.J. Marine toxins that target voltage-gated 
sodium channels. Mar. Drugs 2006, 4, 157–192. 
2. Morales, J.J.; Rodriguez, A.D. The structure of Clathrodin, a novel alkaloid isolated from the 
Caribbean Sea sponge Agelas-Clathrodes. J. Nat. Prod. 1991, 54, 629–631. 
3. Forenza, S.; Minale, L.; Riccio, R. New bromo-pyrrole derivatives from sponge Agelas-Oroides. 
J. Chem. Soc. Chem. Commun. 1971, 1129–1130; doi:10.1039/C29710001129. 
4. Kobayashi, J.; Ohizumi, Y.; Nakamura, H.; Hirata, Y. A novel antagonist of serotonergic 
receptors, Hymenidin, isolated from the Okinawan marine sponge Hymeniacidon sp. Experientia 
1986, 42, 1176–1177. 
5. Rentas, A.L.R.; Rosa, R.; Rodriguez, A.D.; Demotta, G.E. Effect of alkaloid toxins from tropical 
marine sponges on membrane sodium currents. Toxicon 1995, 33, 491–497. 
6. Catterall, W.A. Voltage-gated sodium channels at 60: Structure, function and pathophysiology.  
J. Physiol. 2012, 590, 2577–2589. 
7. Andavan, G.S.B.; Lemmens-Gruber, R. Voltage-gated sodium channels: Mutations, 
channelopathies and targets. Curr. Med. Chem. 2011, 18, 377–397. 
8. Nardi, A.; Damann, N.; Hertrampf, T.; Kless, A. Advances in targeting voltage-gated sodium 
channels with small molecules. Chemmedchem 2012, 7, 1712–1740. 
9. Vimont, A.; Travert, A.; Binet, C.; Pichon, C.; Mialane, P.; Secheresse, F.; Lavalley, J.C. 
Relationship between infrared spectra and stoichiometry of pyridine-H3PW12O40 salts using a 
new TGA-infrared coupling. J. Catal. 2006, 241, 221–224. 
10. McCormack, K.; Santos, S.; Chapman, M.L.; Krafte, D.S.; Marron, B.E.; West, C.W.; Krambis, M.J.; 
Antonio, B.M.; Zellmer, S.G.; Printzenhoff, D.; et al. Voltage sensor interaction site for selective 
small molecule inhibitors of voltage-gated sodium channels. Proc. Natl. Acad. Sci. USA 2013, 
110, E2724–E2732. 
11. Chi, V.; Pennington, M.W.; Norton, R.S.; Tarcha, E.J.; Londono, L.M.; Sims-Fahey, B.; 
Upadhyay, S.K.; Lakey, J.T.; Iadonato, S.; Wulff, H.; et al. Development of a sea anemone toxin 
as an immunomodulator for therapy of autoimmune diseases. Toxicon 2012, 59, 529–546. 
Mar. Drugs 2014, 12 2143 
 
 
12. Pope, J.E.; Deer, T.R. Ziconotide: A clinical update and pharmacologic review.  
Expert Opin. Pharmacother. 2013, 14, 957–966. 
13. De la Vega, R.C.R.; Possani, L.D. Overview of scorpion toxins specific for Na+ channels and 
related peptides: Biodiversity, structure-function relationships and evolution. Toxicon 2005, 46, 
831–844. 
14. Stevens, M.; Peigneur, S.; Tytgat, J. Neurotoxins and their binding areas on voltage-gated sodium 
channels. Front. Pharmacol. 2011, 2, doi:10.3389/fphar.2011.00071. 
15. Tikhonov, D.B.; Zhorov, B.S. Sodium channel activators: Model of binding inside the pore and a 
possible mechanism of action. FEBS Lett. 2005, 579, 4207–4212. 
16. Du, Y.; Garden, D.P.; Wang, L.; Zhorov, B.S.; Dong, K. Identification of new batrachotoxin-sensing 
residues in segment IIIS6 of the sodium channel. J. Biol. Chem. 2011, 286, 13151–13160. 
17. Moczydlowski, E.G. The molecular mystique of tetrodotoxin. Toxicon 2013, 63, 165–183. 
18. Schroif-Gregoire, C.; Travert, N.; Zaparucha, A.; Al-Mourabit, A. Direct access to marine 
pyrrole-2-aminoimidazoles, oroidin, and derivatives, via new acyl-1,2-dihydropyridin intermediates. 
Org. Lett. 2006, 8, 2961–2964. 
19. Olofson, A.; Yakushijin, K.; Horne, D.A. Synthesis of mauritiamine. J. Org. Chem. 1997, 62, 
7918–7919. 
20. Žula, A.; Kikelj, D.; Ilaš, J.J. 2-Aminoimidazoles in medicinal chemistry. Mini Rev. Med. Chem. 
2013, 13, 1921–1943. 
21. Zidar, N.; Jakopin, Ž.; Madge, D.J.; Chan, F.; Tytgat, J.; Peigneur, S.; Sollner Dolenc, M.; 
Tomašić, T.; Ilaš, J.; Pweterlin Mašič, L.; et al. Ligand- and structure-based virtual screening for 
clathrodin-derived human voltage-gated sodium channel modulators. J. Chem. Inf. Model. 2013, 
53, 3223–3232. 
22. Liman, E.R.; Tytgat, J.; Hess, P. Subunit stoichiometry of a mammalian K+ channel determined 
by construction of multimeric cDNAs. Neuron 1992, 9, 861–871. 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
